The director of transplant surgery at NYU Langone Medical Center, Dr. Lewis Teperman has more than 30 years of experience and specializes in hepatobiliary surgery and liver transplants, including living donor transplants. Dr. Lewis Teperman is the recipient of the 2014 Physician of the Year award from the American Liver Foundation (ALF).
Founded in 1976, the American Liver Foundation was the nation’s first voluntary health agency created specifically to study and fight liver disease. Dedicated to increasing education, support, and research for liver disease, the foundation also works to increase public awareness. For more than 30 years, the ALF has provided over 800 scientists and physicians with $24 million in research funding.
The ALF holds a number of events, like the Liver Life Walk, Liver Life Challenge, and Flavors Culinary Experience, throughout the year to raise funds and support for the foundation and the more than 30 million Americans affected by liver disease. The ALF also accepts direct support in the form of donations, honor or memorial gifts, and personal fundraising efforts. To learn more, visit www.liverfoundation.org.
For more than 20 years, Dr. Lewis Teperman has worked in numerous capacities, including that of the NYU Langone Medical Center’s director of transplantation. A liver transplant expert, Dr. Lewis Teperman has also conducted research on the care of patients with liver tumors or liver disease.
According to the American Journal of Managed Care, new agents for the fight against HCV are yielding better results with shorter treatment periods. The introduction of medications like Sofosbuvir (Sovaldi) and Simeprevir (Olysio) signifies a momentous step towards managing a disease that creates an overwhelming demand for liver transplants and claims the lives of an estimated 16,000 Americans per year. Used with Ribavirin and Interferon, these medications have been shown to reduce the effects of HCV and to do so three to six months faster than previous treatments. HCV patients currently receive a third of all available liver transplants in the United States, and these breakthrough treatments can help decrease that demand.
While physicians prescribed Sofosbuvir almost 5,000 times within the first two months of its release, many early-stage patients are choosing to wait for the arrival of next-generation medications on the market. The next wave of medications will offer reduced side effects and even higher success rates in the battle against the slowly progressing viral disease.
Dr. Teperman leads a research study at NYULMC transplant which is looking at how to treat patients with alternatives to Interferon.
Dr. Lewis Teperman is a renowned transplant surgeon in New York, and the author of the 2012 article “Living donation for the very ill patient with type 1 hepatorenal syndrome: Are we ready?” Among his professional circles, he is considered an authority on hepatitis C and liver transplantation.
According to federal health officials, two-thirds of individuals with hepatitis C are between the ages of 45 and 64. The testing for hepatitis C in individuals in this age bracket is crucial; due to the lack of knowledge of the disease during the 1960s and 1970s, many blood transfusions may have been contaminated. Any exchange of blood, including that which might occur in contact sports or in manicure/pedicure procedures, also carries the potential for the exchange of hepatitis C.
Treatments have considerably improved over the last few decades, indicating the possibility for a high quality of life for those diagnosed with hepatitis C. Liver transplant surgery is also an effective way to combat liver failure, so long as the disease is discovered in time.